Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2016 Target Snapshot

Coagulation factor IX · SINGLE PROTEIN · Homo sapiens

1,260Compounds
96Assays
0Approved Drugs
1,210.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Coagulation factor IX shows approved-linked disease relevance led by hemophilia B. 5 more disease programs remain visible in the same review block. 8 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P00740. Start with hemophilia B, then reuse UniProt P00740 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with hemophilia B, then reuse UniProt P00740 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 8 linked drugs
Open source guide
Disease program
hemophilia B

Coagulation factor IX shows approved-linked disease relevance led by hemophilia B. 5 more disease programs remain visible in the same review block. 8 linked drugs remain visible in the same block.

Start review with hemophilia B because it currently carries approved-linked support. Linked drugs include ALBUTREPENONACOG ALFA, COAGULATION FACTOR IX HUMAN, COAGULATION FACTOR IX RECOMBINANT HUMAN, EFTRENONACOG ALFA. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 8 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Coagulation factor IX as ChEMBL target CHEMBL2016, mapped to UniProt P00740. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Coagulation factor IX
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2016
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P00740
Coagulation factor IX
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Coagulation factor IX is the right protein anchor across sources, using UniProt P00740 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why hemophilia B is currently framed as approved-linked support. It currently carries 8 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelCoagulation factor IX
UniProt AccessionP00740
Component TypeProtein
Sequence Length461 aa

Coagulation factor IX

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Coagulation factor IX, mapped to UniProt P00740. Sequence length is 461 aa.

Mapped IDP00740
Review nameCoagulation factor IX
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Coagulation factor IX shows approved-linked disease relevance led by hemophilia B. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
hemophilia B
8 linked drugs · 8 direct · 8 efficacy
Linked drugALBUTREPENONACOG ALFA
Linked drugCOAGULATION FACTOR IX HUMAN
Linked drugCOAGULATION FACTOR IX RECOMBINANT HUMAN
Linked drugEFTRENONACOG ALFA
Approved-linked Approved
hemorrhage
3 linked drugs · 3 direct · 3 efficacy
Linked drugETRANACOGENE DEZAPARVOVEC
Linked drugFIDANACOGENE ELAPARVOVEC
Linked drugVALOCTOCOGENE ROXAPARVOVEC
Approved-linked Approved
Coagulation Protein Disorders
1 linked drug · 1 direct · 1 efficacy
Linked drugCOAGULATION FACTOR IX HUMAN
Approved-linked Approved
hemophilia A
1 linked drug · 1 direct · 1 efficacy
Linked drugVALOCTOCOGENE ROXAPARVOVEC
Approved-linked Approved
inborn error of immunity
1 linked drug · 1 direct · 1 efficacy
Linked drugFIDANACOGENE ELAPARVOVEC
Late clinical Phase III
coronary artery disease
1 linked drug · 1 direct · 1 efficacy
Linked drugPEGNIVACOGIN
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with hemophilia B because it currently carries approved-linked support. Linked drugs include ALBUTREPENONACOG ALFA, COAGULATION FACTOR IX HUMAN, COAGULATION FACTOR IX RECOMBINANT HUMAN, EFTRENONACOG ALFA. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasehemophilia B
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

2
Phase II
Assay Mix

Activity Type Distribution

IC50594.0
KI616.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4107149 10.52 Ki 0.03 Preclinical
CHEMBL4110926 10.4 Ki 0.04 Preclinical
CHEMBL4114881 10.3 Ki 0.05 Preclinical
CHEMBL4112773 10.3 Ki 0.05 Preclinical
CHEMBL4113483 10.22 Ki 0.06 Preclinical
CHEMBL4109568 10.22 Ki 0.06 Preclinical
CHEMBL4108033 10.15 Ki 0.07 Preclinical
CHEMBL4115630 10.1 Ki 0.08 Preclinical
CHEMBL4110983 10.1 Ki 0.08 Preclinical
CHEMBL3948120 10.05 Ki 0.09 Preclinical
Distribution

pChEMBL Value Distribution

42
5.0
51
5.5
86
6.0
102
6.5
118
7.0
168
7.5
200
8.0
107
8.5
35
9.0
11
9.5
pChEMBL
Assay Landscape

Assay Landscape

96
Total Assays
926
Tested Compounds
2
Assay Types
Binding — 95 assays, 926 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 93 926 7.5
assay format 1 0
cell-free format 1 0
ADME — 1 assays, 13 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 1 13 5.8

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine